Healthcare Services

One of the Major Drivers of the Artificial Pancreas Device System Market Is the Impact Of Increasing Pancreatic Cancer Prevalence On The Artificial Pancreas Device System Market

March 30, 2026March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Artificial Pancreas Device System Market By 2030 Starting From Its 2026 Size?

The artificial pancreas device system market has experienced substantial expansion in recent years. Its valuation is projected to increase from $2.06 billion in 2025 to $2.35 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.9%. Historically, this growth has been driven by factors such as the increasing prevalence of diabetes, the early adoption of insulin pump technologies, the expansion of continuous glucose monitoring usage, improvements in medical sensor accuracy, and a growing awareness of automated diabetes management.

The artificial pancreas device system market size is anticipated to undergo significant expansion in the foreseeable future. By 2030, it is projected to reach $3.92 billion, expanding at a compound annual growth rate (CAGR) of 13.7%. This expansion during the forecast period is fueled by several factors, including the escalating requirement for fully automated glucose control, increasing capital allocation in digital diabetes management, the wider adoption of remote patient monitoring, a growing emphasis on individualized insulin treatment, and enhanced regulatory endorsement for advanced diabetes technologies. Prominent trends throughout this period encompass the rising adoption of closed-loop glucose management systems, increasing integration of continuous glucose monitoring (CGM) with insulin pumps, the expanded utilization of predictive algorithms for insulin delivery, the proliferation of wearable devices for diabetes management, and a heightened focus on patient-centered automation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18229&type=smp

What Drivers Are Shaping The Future Growth Of The Artificial Pancreas Device System Market?

The rising occurrence of pancreatic cancer is anticipated to boost the growth of the artificial pancreas device system market in the coming years. Pancreatic cancer is a malignant tumor that originates in the pancreas, a gland located behind the stomach. Its development is influenced by a combination of lifestyle, genetic, medical, and environmental factors, alongside genetic mutations leading to hereditary pancreatitis, which can cause chronic inflammation of the pancreas. An artificial pancreas device system (APDS) is primarily engineered to assist individuals with diabetes in managing their blood sugar levels by autonomously monitoring glucose and delivering the appropriate amount of insulin. For instance, in March 2024, Cancer Australia, a government agency, estimated that 4,506 new cases of pancreatic cancer were diagnosed in 2023, an increase from the 3,751 cases reported over the past five years. Therefore, the increasing prevalence of pancreatic cancer is a significant driver for the growth of the artificial pancreas device system market.

Which Segment Categories Define The Artificial Pancreas Device System Market?

The artificial pancreas device system market covered in this report is segmented –

1) By Device Type: Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems

2) By Treatment Type: Bi-Hormonal, Insulin Only, Hybrid

3) By End-User: Hospitals, Medical Centers, Other End-Users

Subsegments:

1) By Threshold Suspend Device Systems: Insulin Pump with Threshold Suspend, Continuous Glucose Monitoring (CGM) Integrated Systems

2) By Control-To-Range Systems: Hybrid Closed-Loop Systems, Insulin Delivery Systems with Range Control, Real-Time Glucose Adjustment Systems

3) By Control-To-Target Systems: Fully Closed-Loop Artificial Pancreas Systems, Insulin Pumps with Targeted Glucose Control, Automated Glucose Regulation Systems

What Key Developments And Trends Are Impacting The Artificial Pancreas Device System Market?

Major companies within the artificial pancreas device system market are actively developing automated insulin delivery systems to enhance diabetes management by automatically monitoring blood glucose levels and delivering the appropriate amount of insulin. These automated insulin delivery systems are designed to replicate the function of a healthy pancreas, thereby reducing the burden of constant blood sugar monitoring and manual insulin administration for individuals with diabetes. For instance, in May 2023, Beta Bionics, a US-based medical equipment manufacturing company, obtained FDA 510(k) clearance for its iLet Insulin-Only Bionic Pancreas System, an automated insulin delivery device. This particular artificial pancreas system is engineered to autonomously determine and dispense insulin doses to control blood glucose levels. Functioning as a closed-loop system, it automatically adjusts insulin delivery based on the user’s glucose levels, which are measured by a connected continuous glucose monitor (CGM). The system only requires the user’s body weight and an estimated meal size to automatically modify insulin delivery.

Who Are The Top Companies Competing In The Artificial Pancreas Device System Market?

Major companies operating in the artificial pancreas device system market are Medtronic plc, Abbott Laboratories, DexCom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Roche Diabetes Care, Ypsomed, SOOIL Development, Beta Bionics Inc., Bigfoot Biomedical Inc., Diabeloop SA, Inreda Diabetic B.V., Defymed SAS, DreaMed Diabetes Ltd., Medtrum Technologies Inc., EOFlow Co. Ltd., Cellnovo, Pancreum Inc., Admetsys Corporation, GlucoModicum, MicroTech Medical

Read the full artificial pancreas device system market report here:

https://www.thebusinessresearchcompany.com/report/artificial-pancreas-device-system-global-market-report

Which Geographic Regions Are Influencing Demand In The Artificial Pancreas Device System Market?

North America was the largest region in the artificial pancreas device system market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial pancreas device system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Artificial Pancreas Device System Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18229&type=smp

Browse Through More Reports Similar to the Global Artificial Pancreas Device System Market 2026, By The Business Research Company

Diabetes Care Devices Market

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Gastrointestinal Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report

Hepato Pancreatico Biliary Hpb Surgeries Surgical Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/hepato-pancreatico-biliary-hpb-surgeries-surgical-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795